Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: A multicenter retrospective study

Eribulin methylate (eribulin) improved the overall survival (OS) of eribulin-treated patients with HER2- negative advanced breast cancer (ABC) in prospective and retrospective studies. However, the effect of eribulin on OS as first-line chemotherapy and the characteristics of the patients who benefited from eribulin remain unclear.
Nội dung trích xuất từ tài liệu:
Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: A multicenter retrospective study Nakamoto et al. BMC Cancer (2022) 22:31 https://doi.org/10.1186/s12885-021-09137-0 RESEARCH ARTICLE Open Access Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study Shogo Nakamoto1,2*  , Junichiro Watanabe1  , Shoichiro Ohtani3, Satoshi Morita4 and Masahiko Ikeda2  Abstract  Background:  Eribulin methylate (eribulin) improved the overall survival (OS) of eribulin-treated patients with HER2- negative advanced breast cancer (ABC) in prospective and retrospective studies. However, the effect of eribulin on OS as first-line chemotherapy and the characteristics of the patients who benefited from eribulin remain unclear. Methods:  Between January 2011 and December 2016, 301 patients with HER2-negative ABC who started first-line chemotherapy at 3 institutions were retrospectively evaluated for OS from the initiation of first-line chemotherapy. Results:  We identified 172 patients (119 estrogen receptor-positive [ER+], 47 ER−, 6 unknown) who received eribulin (eribulin group) and 129 patients (92 ER+, 31 ER−, 6 unknown) who did not receive eribulin (non-eribulin group). The median OS from the initiation of first-line chemotherapy in the two groups was not statistically significant (869 vs. 744 days, P = 0.47, log-rank); however, in patients who received eribulin in later lines (≥3rd-line) and who had a history of perioperative chemotherapy with anthracycline- and/or taxane-based regimens, the median OS improved (1001 vs. 744 days, P = 0.037; and 834 vs. 464 days, respectively P = 0.032, respectively; Wilcoxon). Multivariate analyses revealed that a history of perioperative chemotherapy with anthracycline- and/or taxane-based regimens was a pre- dictive factor (hazard ratio, 0.39; 95% confidence interval, 0.21–0.70) for OS. Conclusions:  This study successfully identified subgroups of HER2− ABC patients with improved OS by eribulin therapy. Selecting patients according to their background and line of treatment will maximize the efficacy of eribulin therapy. Keywords:  Advanced breast cancer, Eribulin, HER2-negative, Overall survival, Real world Background with a history of anthracycline- and/or taxane-based Eribulin methylate (eribulin) is a novel antitubulin agent therapy [1, 2]. In the EMBRACE study, the efficacy of widely used for patients with human epidermal growth eribulin was compared with treatment of the physician’s factor receptor-2 negative (HER2−) advanced breast can- choice (TPC) in patients with heavily pretreated HER2− cer (ABC). It is a preferred treatment option for patients ABC. Although there was no statistically significant difference in progression-free survival (PFS), overall sur- vival (OS) was significantly improved in patients treated *Correspondence: p92c9f20@s.okayama-u.ac.jp with eribulin compared with those receiving TPC treat- 1 Division of Breast Oncology, Shizuoka Cancer Center, 1007 ment (hazard ratio [HR], 0.81; 95% confidence interval Shimonagakubo, Nagaizumi, Shizuoka 411‑8777, Japan [CI], 0.66–0.99; P = 0.041, log-rank) [3]. In study 301, Full list of author information is available at the end of the article © The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons l ...